NOVARTIS N (NOVN.SW) Financials
NOVN.SW Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 84.0 billion | 44.7 billion |
2023-09-30 | 103.2 billion | 68.2 billion |
2023-06-30 | 99.8 billion | 53.1 billion |
2023-03-31 | 102.6 billion | 54.9 billion |
NOVN.SW Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 1.5 billion | 208.5 million |
2023-09-30 | 4.3 billion | 187.7 million |
2023-06-30 | 2.3 billion | 209.5 million |
2023-03-31 | 2.3 billion | 181.9 million |
NOVN.SW Net Income
Date | Net Income |
---|---|
2023-12-31 | 2.2 billion |
2023-09-30 | 1.4 billion |
2023-06-30 | 2.1 billion |
2023-03-31 | 2.1 billion |
NOVN.SW Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 11.7 billion | - | 1.5 billion |
2023-09-30 | 11.6 billion | 17.9 billion | 1.5 billion |
2023-06-30 | 10.0 billion | 17.8 billion | 1.6 billion |
2023-03-31 | 11.2 billion | 20.1 billion | 1.7 billion |
NOVN.SW Shares Outstanding
NOVN.SW Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 658.4 million | 2.2 billion | 2.9 billion | - |
2023-09-30 | 625.3 million | 3.6 billion | 2.8 billion | - |
2023-06-30 | 895.4 million | 2.3 billion | 3.3 billion | - |
2023-03-31 | 429.6 million | 2.6 billion | 3.1 billion | - |
NOVN.SW Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 9.9 billion | 2.5 billion |
2023-09-30 | 11.1 billion | 2.9 billion |
2023-06-30 | 12.5 billion | 3.9 billion |
2023-03-31 | 12.1 billion | 3.6 billion |
NOVN.SW
Price: CHF89.04
Dividend Yield: 0.05%
Forward Dividend Yield: 3.75%
Payout Ratio: 88.00%
Dividend Per Share: 3.30 CHF
Earnings Per Share: 3.75 CHF
P/E Ratio: 24.52
Exchange: EBS
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 3.9 million
Market Capitalization: 176.0 billion
Average Dividend Frequency: 1
Years Paying Dividends: 28
DGR3: 2.67%
DGR5: 2.63%
DGR10: 3.24%
DGR20: 5.75%